Get the Stockscreener App
12.96
2.61%
0.33
After Hours:
12.96
Lyell Immunopharma Inc stock is traded at $12.96, with a volume of 110.58K.
It is up +2.61% in the last 24 hours and up +11.63% over the past month.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
See More
Previous Close:
$12.63
Open:
$12.77
24h Volume:
110.58K
Relative Volume:
0.74
Market Cap:
$317.58M
Revenue:
$31,000
Net Income/Loss:
$-246.41M
P/E Ratio:
-1.0175
EPS:
-12.7377
Net Cash Flow:
$-134.42M
1W Performance:
+0.31%
1M Performance:
+11.63%
6M Performance:
-48.73%
1Y Performance:
+4.35%
1-Day Range:
$12.60
$13.05
1-Week Range:
$12.45
$14.14
52-Week Range:
$9.28
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Name
Lyell Immunopharma Inc
Sector
Industry
Phone
650 695-0677
Address
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
12.96 | 309.49M | 31,000 | -246.41M | -134.42M | -12.74 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Needham | Buy |
| Mar-09-26 | Initiated | Citizens | Mkt Outperform |
| Dec-09-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-30-24 | Downgrade | BofA Securities | Buy → Underperform |
| Jun-27-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-28-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-14-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-11-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-17-22 | Initiated | H.C. Wainwright | Buy |
| Jul-12-21 | Initiated | BofA Securities | Buy |
| Jul-12-21 | Initiated | Goldman | Buy |
| Jul-12-21 | Initiated | JP Morgan | Overweight |
| Jul-12-21 | Initiated | Morgan Stanley | Overweight |
View All
Lyell Immunopharma Inc Stock (LYEL) Latest News
Form 4 Lyell Immunopharma Inc For: 27 July By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (LYEL) holder pays broker with 44,000 shares - Stock Titan
Broker commission transfer of 38,500 shares in Lyell Immunopharma (LYEL) - Stock Titan
Lyell Immunopharma Inc (LYEL) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Lyell Immunopharma Inc (LYEL) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Lyell Immunopharma Inc (LYEL) Cash Flow - TradingKey
Lyell Immunopharma Inc (LYEL) Institutional Confidence - TradingKey
Lyell Immunopharma Inc (LYEL) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
TradingKey - TradingKey
Lyell Immunopharma Inc (LYEL) Balance Sheet - TradingKey
LYEL|Lyell Immunopharma Inc|Price:12.615|Chg%:-0.165 - TradingKey
Lyell Immunopharma, Inc. Revenue Breakdown – NASDAQ:LYEL - TradingView
Lyell Immunopharma Inc (LYEL) Valuation: PE, PB & Fair Value Analysis - TradingKey
Lyell Immunopharma Inc (LYEL) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
B. Riley Securities Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $44 - Moomoo
LYEL Initiates Coverage by B. Riley Securities -- Price Target A - GuruFocus
Stifel initiates Lyell Immunopharma stock with buy, $44 target - Investing.com India
Lyell Immunopharma, Inc. SEC Filing (Jul 22, 2026) - Stock Titan
Stifel initiates Lyell Immunopharma stock with buy, $44 target By Investing.com - Investing.com Canada
Form 4 Lyell Immunopharma Inc For: 21 July By Investing.com - Investing.com Nigeria
Innovative cellular therapeutics, Lyell director, sells $137 in stock - Investing.com
Innovative cellular therapeutics, Lyell director, sells $137 in stock By Investing.com - Investing.com Canada
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma share sale worth $137 - Bitget
Insider Sell: Innovative Cellular Therapeutics Holdings Ltd Redu - GuruFocus
Lyell Immunopharma (LYEL) insider entity sells 10 shares under plan - Stock Titan
Form 4 Lyell Immunopharma Inc For: 17 July By Investing.com - Investing.com Nigeria
Innovative cellular therapeutics sells $137 in Lyell Immunopharma stock - Investing.com UK
Innovative cellular therapeutics sells $137 in Lyell Immunopharma stock By Investing.com - Investing.com South Africa
Innovative Cellular Therapeutics Holdings reports Lyell Immunopharma common share disposal worth $137.3 - Bitget
Innovative Cellular trims Lyell Immunopharma (LYEL) stake with small share sale - Stock Titan
Innovative Cellular Therapeutics Holdings Ltd Net Worth (2026) - GuruFocus
Form S-3 Lyell Immunopharma Inc For: 13 July By Investing.com - Investing.com Nigeria
Lyell Immunopharma (NASDAQ: LYEL) files resale shelf for 1.1M shares - Stock Titan
Lyell Immunopharma (LYEL) Surges Over 13% as Stock Breaks Above Key SupportVol Target Rebalance - dars.gov.et
LYEL Q1 2026 Earnings: Narrower Loss Surprises as Clinical Pipeline AdvancesHigh Growth Earnings - dars.gov.et
Lyell Immunopharma updates pipeline strategy as cell therapy field evolves - Ad-hoc-news.de
LYELLyell Immunopharma Inc Volatility & Greeks - Finviz
Wall Street Analysts Think Lyell Immunopharma (LYEL) Could Surge 176.02%: Read This Before Placing a Bet - Yahoo Finance
Form 4 Lyell Immunopharma Inc For: 1 July By Investing.com - Investing.com South Africa
Innovative Cellular Therapeutics moves 76K Lyell (LYEL) shares as broker commission - Stock Titan
Lyell Immunopharma stock maintained at Market Outperform by Citizens By Investing.com - Investing.com India
Lyell Immunopharma stock maintained at Market Outperform by Citizens - Investing.com Canada
Lyell at H.C. Wainwright cell therapy conference: data and catalysts By Investing.com - Investing.com South Africa
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Value Benchmark - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Microcap Value Benchmark Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell Microcap Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS: LYEL) added to Russell 2000 Dynamic Index - marketscreener.com
Lyell Immunopharma, Inc.(NasdaqGS:LYEL) added to Russell Small Cap Completeness Index - marketscreener.com
Lyell Immunopharma Inc Stock (LYEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):